The American Diabetes Association (ADA) regularly publishes standards of care and has just added CDO Therapy to their 2023 Standards of Care for the treatment of diabetic foot ulcers. The ADA article cites recent high level evidence for this decision:
“Topical oxygen therapy has been studied rather vigorously in recent years, with several high-quality RCT’s and at least five systematic reviews and meta-analyses all supporting its efficacy in healing chronic DFU’s at 12 weeks.” Diabetes Care, Volume 46, p. S212, January 2023. https://doi.org/10.2337/dc23-S012
This evidence includes EO2’s study published in the September of 2018 issue of the Journal of Wound Care, cited by CMS as the “Gold Standard” for how studies should be designed.
The ADA Standards of Care article goes on to state:
“Importantly, topical oxygen therapy devices provide for home-based therapy rather than the need for daily visits to specialized centers.” (such as Hyperbaric Oxygen) “Very high participation with very few reported adverse events combined with improved healing rates makes this therapy another attractive option for advanced wound care.”
The physicians who have experienced the significant impact of CDO therapy, including faster healing, reduced scarring and pain, have known that this treatment should be considered the standard of care for most wound types. Having an independent, clinically oriented organization like the American Diabetes Association make the same recommendation highlights the not only the clinical efficacy, yet also the rapidly growing adoption of CDO therapy as a standard of care.